MEDICAL COLLEGE OF WISCONSIN

MEDICAL COLLEGE OF WISCONSIN logo
🇺🇸United States
Ownership
Private
Established
1893-01-01
Employees
5K
Market Cap
-
Website
http://www.mcw.edu
onclive.com
·

Data Continue to Help Shape CDK4/6 Inhibitor Selection, Sequencing in HR+ Breast Cancer

CDK4/6 inhibitors (ribociclib, abemaciclib, palbociclib) are integrated into HR+/HER2- breast cancer treatment. First-line therapy typically combines a CDK4/6 inhibitor with an AI, with ribociclib preferred due to significant OS improvement in MONALEESA-2. Contraindications include cardiac issues or QTc prolongation for ribociclib, which may lead to abemaciclib or palbociclib use. Post-CDK4/6 inhibitor treatment options include switching inhibitors or adding targeted agents based on mutations. Adjuvant use of abemaciclib and ribociclib has shown reduced recurrence risk in high-risk patients.
urotoday.com
·

Biopsy-based Basal-luminal Subtyping Classifier in High-risk Prostate Cancer

PSC genomic classifier predicts prognosis and benefits of LT-ADT in high-risk PCa, with basal subtype showing worse outcomes and greater benefit from LT-ADT, suggesting personalized ADT recommendations.

Dignity Health hires CEO for hospitals in Bakersfield, and more | MED MOVES

Simon Ratliff appointed CEO of Dignity Health’s Bakersfield hospitals; Chris Woleske to retire from Emplify Health; Kert Anzilotti named president of ChristianaCare’s medical group; Joseph Hill becomes chief culture, equity and belonging officer at Cone Health.
targetedonc.com
·

Next Steps for Cilta-Cel and CARTITUDE-4 in Multiple Myeloma

Binod Dhakal discusses next steps for evaluating cilta-cel in multiple myeloma, emphasizing the importance of timely access and patient communication. He highlights potential side effects and the evolving role of CAR T-cell therapy, particularly for high-risk patients. Dhakal looks forward to data from CARTITUDE-4 and studies examining CAR T-cell therapy in the frontline setting.
globenewswire.com
·

IMUNON Reports Third Quarter 2024 Financial Results and Provides Business Updates

IMUNON reported Q3 2024 financial results, highlighting progress with IMNN-001 in advanced ovarian cancer and IMNN-101, a seasonal COVID-19 booster. IMNN-001 showed an 11.1-month OS improvement in OVATION 2 Study, with plans to start a Phase 3 study in Q1 2025. The company raised $10 million in a registered direct financing and added key leadership to support operational excellence.
ajmc.com
·

Breakthroughs in Pulmonary Disease, Advancements in PE Management at CHEST 2024

CHEST 2024 highlighted advancements in pulmonary disease, PE, and pulmonary hypertension, focusing on personalized care, clinical trials, and new COPD treatments. Discussions included sleep medicine, racial disparities in pulmonary care, and tailored learning opportunities.

New Regimen Could Improve Outcomes in Transplantation From Half-Matched Donors

The CAST regimen (post-transplant cyclophosphamide, abatacept, and tacrolimus) after haploidentical HSCT shows promising results in preventing GVHD, with reduced relapse rates and improved survival compared to standard regimens. This could address disparities in donor availability, especially for minority groups.
morningstar.com
·

Satellite Symposium Addresses The Role of Advanced Multiplex Molecular Testing in ...

Satellite symposium at IDWeek 2024 addresses advanced multiplex molecular testing's role in diagnostic stewardship, planned by Medavera, Inc.
pmlive.com
·

J&J and Legend share long-term results for Carvykti in phase 3 multiple myeloma study

J&J and Legend Biotech report positive long-term results for Carvykti, a BCMA-directed T-cell immunotherapy for multiple myeloma, showing a 45% reduction in death risk compared to standard therapies after a median follow-up of almost three years.
cgtlive.com
·

Cilta-cel Boosts Overall Survival in New Early Line Multiple Myeloma Data

Janssen and Legend Biotech's cilta-cel (Carvykti) showed improved overall survival (OS) in lenalidomide-refractory multiple myeloma (MM) patients compared to standard-of-care (SOC) therapy in the phase 3 CARTITUDE-4 trial, with a 45% reduced risk of death. Cilta-cel also demonstrated better progression-free survival (PFS) and higher complete response rates. The therapy is approved in the U.S., EU, and China for specific MM patient groups.
© Copyright 2024. All Rights Reserved by MedPath